Vytrus Biotech, S.A.
Vytrus Biotech develops and manufactures ingredients that cosmetic brands use in skin and hair products. It grows plant cells and uses other biotechnology processes to produce compounds for formulations such as moisturisers and scalp treatments.
Overview
Latest results
Latest financial publication
9M 2026 financial results
Investment Thesis
Turning cosmetic biotechnology into repeat ingredient sales
European Tech Equities analysis ·
The investment case
The case is a specialist ingredient business that can spread research and production costs over growing sales. Unlike a drug developer awaiting approval, Vytrus already sells products and generates profit. Sustaining that growth requires repeat demand, successful launches and disciplined capacity spending.
Business progress
Preliminary sales for the first nine months of 2026 rose 34% to €8.6 million, with €4.88 million of EBITDA and €3.43 million of net profit. Growth was not uniform: US sales fell 14%. The September release is an unaudited trading update, not a complete set of statements.
Customer demand
Customers need ingredients that work in their formulas, arrive reliably and support credible product claims. Distributor orders can vary with inventory and launch schedules. Consumer interest in biotechnology is useful only when brands convert it into products and repeat purchases.
Financial position
The reviewed first-half accounts show €2.58 million net profit and €2.58 million operating cash flow. Cash was €3.88 million at June 2026. Cash investment in tangible and intangible assets was €1.78 million; capitalised development means EBITDA alone does not show all research spending.
Value and risks
Assessment should connect growth and margins with cash remaining after development and factory investment. A small company can grow quickly from a low base, but distributor dependence, competing ingredients and capacity execution matter. An award or a product launch is not a substitute for repeat sales.
What would weaken the case
- Distributor demand can fluctuate with inventories.
- Development capitalisation makes EBITDA an incomplete measure of cash generation.
- New platforms need customer adoption and reliable production at scale.
Sources
Financials
The business in numbers
Latest
Income statement
| For the periodEUR million | 9M 2026 (preliminary) |
|---|---|
| Revenue | 8.60 |
| EBITDA | 4.88 |
| EBITDA margin | 56.7% |
| Net income | 3.43 |
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
Individual accounts under Spanish accounting rules. The September update includes only preliminary, unaudited revenue, EBITDA and net profit; detailed statements are from June and received a limited review. Development costs are partly capitalised.
Annual
Income statement
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
Individual accounts under Spanish accounting rules. The September update includes only preliminary, unaudited revenue, EBITDA and net profit; detailed statements are from June and received a limited review. Development costs are partly capitalised.
Half-year
Income statement
Cash flow
Balance sheet
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
Individual accounts under Spanish accounting rules. The September update includes only preliminary, unaudited revenue, EBITDA and net profit; detailed statements are from June and received a limited review. Development costs are partly capitalised.
Year to date
Income statement
| For the periodEUR million | 9M 2026 (preliminary) |
|---|---|
| Revenue | 8.60 |
| EBITDA | 4.88 |
| EBITDA margin | 56.7% |
| Net income | 3.43 |
Sources and details
Each statement retains its reporting period. Charts use comparable periods and a shared accounting basis; a dash means the figure has not been verified on European Tech Equities.
Calculated: margins = profit ÷ revenue; free cash flow = operating cash flow less capital expenditure; net debt uses the issuer-reported measure when supplied, otherwise debt less cash; liabilities = assets less equity. The company-specific notes explain what debt includes. Negative net debt represents net cash. Quarterly flows cover each individual quarter; balance sheet figures are at period end.
Individual accounts under Spanish accounting rules. The September update includes only preliminary, unaudited revenue, EBITDA and net profit; detailed statements are from June and received a limited review. Development costs are partly capitalised.
Performance
About these figures
Dates link to the original reports. Bars compare the same period a year earlier, on a consistent accounting basis. Arrows show whether the number rose or fell, not whether it is good or bad for the business.
Research & updates
Interviews
Interviews are coming soon
No interviews with Vytrus Biotech, S.A. have been published yet.
Sources
Sources & data dates
Financial figures link to the company’s publications and retain their reporting period. Share prices have their own closing dates.
9M 2026 (preliminary) · Published Nov 5, 2026 · Checked Nov 15, 2026
H1 2025 · Published Oct 21, 2026 · Checked Nov 15, 2026
H1 2026 · Published Oct 21, 2026 · Checked Nov 15, 2026
FY 2024 · Published Mar 25, 2026 · Checked Nov 15, 2026
FY 2025 · Published Mar 25, 2026 · Checked Nov 15, 2026
Checked 2026-11-15
Checked 2026-11-15
Checked 2026-11-15
Checked 2026-11-15
